Comings DE, Wu S, Rostamkhani M, McGue M, Lacono WG, Cheng LS, MacMurray JP (January 2003). "Role of the cholinergic muscarinic 2 receptor (CHRM2) gene in cognition". Molecular Psychiatry. 8 (1): 10–11. doi:10.1038/sj.mp.4001095. PMID12556901. S2CID22314941.
Dick DM, Aliev F, Kramer J, Wang JC, Hinrichs A, Bertelsen S, et al. (March 2007). "Association of CHRM2 with IQ: converging evidence for a gene influencing intelligence". Behavior Genetics. 37 (2): 265–272. doi:10.1007/s10519-006-9131-2. PMID17160701. S2CID9353852.
Lind PA, Luciano M, Horan MA, Marioni RE, Wright MJ, Bates TC, et al. (September 2009). "No association between Cholinergic Muscarinic Receptor 2 (CHRM2) genetic variation and cognitive abilities in three independent samples". Behavior Genetics. 39 (5): 513–523. doi:10.1007/s10519-009-9274-z. PMID19418213. S2CID2523697.
Scapecchi S, Matucci R, Bellucci C, Buccioni M, Dei S, Guandalini L, et al. (March 2006). "Highly chiral muscarinic ligands: the discovery of (2S,2'R,3'S,5'R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M2 partial agonist". Journal of Medicinal Chemistry. 49 (6): 1925–1931. doi:10.1021/jm0510878. PMID16539379.
Matera C, Flammini L, Quadri M, Vivo V, Ballabeni V, Holzgrabe U, et al. (March 2014). "Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity". European Journal of Medicinal Chemistry. 75: 222–232. doi:10.1016/j.ejmech.2014.01.032. PMID24534538.
Cristofaro I, Spinello Z, Matera C, Fiore M, Conti L, De Amici M, et al. (September 2018). "Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells". Neurochemistry International. 118: 52–60. doi:10.1016/j.neuint.2018.04.010. PMID29702145. S2CID207125517.
Riefolo F, Matera C, Garrido-Charles A, Gomila AM, Sortino R, Agnetta L, et al. (May 2019). "Optical Control of Cardiac Function with a Photoswitchable Muscarinic Agonist". Journal of the American Chemical Society. 141 (18): 7628–7636. doi:10.1021/jacs.9b03505. hdl:2445/147236. PMID31010281. S2CID128361100.
Melchiorre C, Angeli P, Lambrecht G, Mutschler E, Picchio MT, Wess J (December 1987). "Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine". European Journal of Pharmacology. 144 (2): 117–124. doi:10.1016/0014-2999(87)90509-7. PMID3436364.
Riefolo F, Matera C, Garrido-Charles A, Gomila AM, Sortino R, Agnetta L, et al. (May 2019). "Optical Control of Cardiac Function with a Photoswitchable Muscarinic Agonist". Journal of the American Chemical Society. 141 (18): 7628–7636. doi:10.1021/jacs.9b03505. hdl:2445/147236. PMID31010281. S2CID128361100.
Comings DE, Wu S, Rostamkhani M, McGue M, Lacono WG, Cheng LS, MacMurray JP (January 2003). "Role of the cholinergic muscarinic 2 receptor (CHRM2) gene in cognition". Molecular Psychiatry. 8 (1): 10–11. doi:10.1038/sj.mp.4001095. PMID12556901. S2CID22314941.
Dick DM, Aliev F, Kramer J, Wang JC, Hinrichs A, Bertelsen S, et al. (March 2007). "Association of CHRM2 with IQ: converging evidence for a gene influencing intelligence". Behavior Genetics. 37 (2): 265–272. doi:10.1007/s10519-006-9131-2. PMID17160701. S2CID9353852.
Lind PA, Luciano M, Horan MA, Marioni RE, Wright MJ, Bates TC, et al. (September 2009). "No association between Cholinergic Muscarinic Receptor 2 (CHRM2) genetic variation and cognitive abilities in three independent samples". Behavior Genetics. 39 (5): 513–523. doi:10.1007/s10519-009-9274-z. PMID19418213. S2CID2523697.
Douglas CL, Baghdoyan HA, Lydic R (December 2001). "M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57BL/6J mouse". The Journal of Pharmacology and Experimental Therapeutics. 299 (3): 960–966. PMID11714883.
Scapecchi S, Matucci R, Bellucci C, Buccioni M, Dei S, Guandalini L, et al. (March 2006). "Highly chiral muscarinic ligands: the discovery of (2S,2'R,3'S,5'R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M2 partial agonist". Journal of Medicinal Chemistry. 49 (6): 1925–1931. doi:10.1021/jm0510878. PMID16539379.
Matera C, Flammini L, Quadri M, Vivo V, Ballabeni V, Holzgrabe U, et al. (March 2014). "Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity". European Journal of Medicinal Chemistry. 75: 222–232. doi:10.1016/j.ejmech.2014.01.032. PMID24534538.
Cristofaro I, Spinello Z, Matera C, Fiore M, Conti L, De Amici M, et al. (September 2018). "Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells". Neurochemistry International. 118: 52–60. doi:10.1016/j.neuint.2018.04.010. PMID29702145. S2CID207125517.
Riefolo F, Matera C, Garrido-Charles A, Gomila AM, Sortino R, Agnetta L, et al. (May 2019). "Optical Control of Cardiac Function with a Photoswitchable Muscarinic Agonist". Journal of the American Chemical Society. 141 (18): 7628–7636. doi:10.1021/jacs.9b03505. hdl:2445/147236. PMID31010281. S2CID128361100.
Melchiorre C, Angeli P, Lambrecht G, Mutschler E, Picchio MT, Wess J (December 1987). "Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine". European Journal of Pharmacology. 144 (2): 117–124. doi:10.1016/0014-2999(87)90509-7. PMID3436364.
ncbi.nlm.nih.gov
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Comings DE, Wu S, Rostamkhani M, McGue M, Lacono WG, Cheng LS, MacMurray JP (January 2003). "Role of the cholinergic muscarinic 2 receptor (CHRM2) gene in cognition". Molecular Psychiatry. 8 (1): 10–11. doi:10.1038/sj.mp.4001095. PMID12556901. S2CID22314941.
Dick DM, Aliev F, Kramer J, Wang JC, Hinrichs A, Bertelsen S, et al. (March 2007). "Association of CHRM2 with IQ: converging evidence for a gene influencing intelligence". Behavior Genetics. 37 (2): 265–272. doi:10.1007/s10519-006-9131-2. PMID17160701. S2CID9353852.
Lind PA, Luciano M, Horan MA, Marioni RE, Wright MJ, Bates TC, et al. (September 2009). "No association between Cholinergic Muscarinic Receptor 2 (CHRM2) genetic variation and cognitive abilities in three independent samples". Behavior Genetics. 39 (5): 513–523. doi:10.1007/s10519-009-9274-z. PMID19418213. S2CID2523697.
Cristofaro I, Spinello Z, Matera C, Fiore M, Conti L, De Amici M, et al. (September 2018). "Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells". Neurochemistry International. 118: 52–60. doi:10.1016/j.neuint.2018.04.010. PMID29702145. S2CID207125517.
Riefolo F, Matera C, Garrido-Charles A, Gomila AM, Sortino R, Agnetta L, et al. (May 2019). "Optical Control of Cardiac Function with a Photoswitchable Muscarinic Agonist". Journal of the American Chemical Society. 141 (18): 7628–7636. doi:10.1021/jacs.9b03505. hdl:2445/147236. PMID31010281. S2CID128361100.